September 22, 2020
U.S. Securities and Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
| Attn: | Mr. Alan Campbell Ms. Christine Westbrook Mr. David Burton Ms. Mary Mast
| |
| Re: | Orphazyme A/S Registration Statement on Form F-1, as amended File No. 333-248607 |
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Orphazyme A/S that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Daylight Time, on September 24, 2020, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 937 copies of the Preliminary Prospectus dated September 21, 2020 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.
Very truly yours,
BOFA SECURITIES, INC.
COWEN AND COMPANY, LLC
GUGGENHEIM SECURITIES, LLC
As Representatives of the several underwriters
[Signature Pages Follow]
BOFA SECURITIES, INC. | ||
| By: | /s/ Michele A.H. Allong | |
| Name: Michele A.H. Allong | ||
| Title: Authorized Signatory | ||
| COWEN AND COMPANY, LLC | ||
| By: | /s/ Tanya Joseph | |
| Name: Tanya Joseph | ||
| Title: Managing Director | ||
| GUGGENHEIM SECURITIES, LLC | ||
| By: | /s/ Stuart Duty | |
| Name: Stuart Duty | ||
| Title: Senior Managing Director | ||
As representatives of the several underwriters.
cc: Ilir Mujalovic, Partner, Shearman & Sterling LLP
[Signature Page to Acceleration Request Letter]
